Turbulent market forces Biolex to scrap IPO

The turbulent stock market has claimed another biotech victim. Biolex Therapeutics says it is dropping its bid to go public, the result of some lethal market rip tides that have already spurred more than a dozen companies to surrender their IPOs. Biolex and OctoPlus have been pushing the development of Locteron, an experimental therapy for hepatitis C.

- here's the report from the Charlotte Observer

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.